Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
71258-0015-22 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
70860-0214-61 70860-0214 Melphalan hydrochloride Melphalan hydrochloride 50.0 mg/10ml Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2019 Oct. 31, 2025 In Use
00002-5340-60 00002-5340 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-5562-60 00002-5562 Selpercatinib RETEVMO 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6082-60 00002-6082 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6120-60 00002-6120 Selpercatinib RETEVMO 120.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00009-0082-02 00009-0082 Irinotecan hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 24, 2024 In Use
00069-0252-30 00069-0252 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0353-30 00069-0353 Talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0454-30 00069-0454 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0546-30 00069-0546 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0655-30 00069-0655 Talazoparib Talzenna 0.75 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0757-30 00069-0757 Talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00078-1196-20 00078-1196 Asciminib SCEMBLIX 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral April 18, 2024 In Use
00143-9167-01 00143-9167 Eribulin mesylate ERIBULIN MESYLATE 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous June 28, 2024 In Use
00245-0822-30 00245-0822 Everolimus TORPENZ 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0823-30 00245-0823 Everolimus TORPENZ 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0824-30 00245-0824 Everolimus TORPENZ 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0825-30 00245-0825 Everolimus TORPENZ 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00310-9501-01 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov. 16, 2023 In Use
00310-9501-95 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Feb. 1, 2024 In Use
00480-3290-01 00480-3290 Paclitaxel Paclitaxel 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous July 2, 2024 In Use
59651-0464-28 59651-0464 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0464-29 59651-0464 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0465-28 59651-0465 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0465-29 59651-0465 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
00781-3520-91 00781-3520 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2024 May 25, 2024 In Use
00781-3528-10 00781-3528 Cyclophosphamide Cyclophosphamide 500.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use
00781-3529-10 00781-3529 Cyclophosphamide Cyclophosphamide 1000.0 mg/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use
00781-3530-10 00781-3530 Cyclophosphamide Cyclophosphamide 2000.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use
00832-0532-09 00832-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 17, 2024 In Use
00832-0533-03 00832-0533 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 17, 2024 In Use
31722-0263-30 31722-0263 ERLOTINIB ERLOTINIB 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
31722-0264-30 31722-0264 ERLOTINIB ERLOTINIB 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
31722-0265-30 31722-0265 ERLOTINIB ERLOTINIB 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
59651-0466-28 59651-0466 SUNITINIB MALATE SUNITINIB MALATE 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0466-29 59651-0466 SUNITINIB MALATE SUNITINIB MALATE 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0467-28 59651-0467 SUNITINIB MALATE SUNITINIB MALATE 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0467-29 59651-0467 SUNITINIB MALATE SUNITINIB MALATE 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
60505-6287-02 60505-6287 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 23, 2024 In Use
60505-6287-04 60505-6287 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 23, 2024 In Use
62332-0730-31 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
62332-0730-36 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-31 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-36 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
70377-0010-22 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0010-11 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0011-22 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0011-11 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use

Found 10,000 results in 6 milliseconds — Export these results